Cambridge-based AI Drug turnaround company Ignota Labs has made an audacious bid to revive failed assets from US company ...
Kronos, once valued at $3.5B, Had Two Phase 2 Stage Assets Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos's clinical assets, istisociclib, a CDK9 inhibitor, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback